Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Details

CPVT is a channelopathy characterized by exercise- or emotion-triggered polymorphic or bidirectional ventricular tachycardia in the absence of structural heart disease or QT prolongation at rest. It is one of the most prevalent causes of SCD in individuals <35 years without structural heart disease, responsible for ~15% of sudden cardiac deaths in youth.

Key Facts

• Prevalence: ~1:10,000. Average age of symptom onset: 7–12 years; ~60% have first syncope by age 20. Up to 50% mortality by age 35 if unrecognized. (sources/channelopathies-jaha-2025)
• Frequently misdiagnosed as epilepsy (seizure-like syncope) or vasovagal syncope. (sources/channelopathies-jaha-2025)
• Genetics: RYR2 gain-of-function mutations (CPVT1) account for ~50–60%; autosomal dominant. CASQ2 loss-of-function is second most common (~5%); autosomal recessive with more severe, earlier phenotype and greater beta-blocker resistance. ClinGen Gene-Disease Validity (2026-05-09): Definitive: RYR2 (AD, CPVT1), CASQ2 (AR, CPVT2 — also moderate for AD CASQ2), TECRL (AR, CPVT3), TRDN (AR, CPVT5). Moderate: CALM1, CALM2, CALM3 (all AD). Disputed: PKP2, KCNJ2 (both disputing 01/20/2021). ANK2 previously attributed to LQT4 has disputed CPVT causation. See concepts/ClinGen-Gene-Disease-Validity and sources/clingen-summary-2026-05-09. (sources/channelopathies-jaha-2025, sources/arrhythmia-genetics-mgenetik-2025, sources/clingen-summary-2026-05-09, rating: high)
• Mechanism (RYR2) — detailed DAD pathway: RYR2 GOF → SR Ca²⁺ overload during adrenergic stimulation → spontaneous diastolic Ca²⁺ sparks coalesce into intracellular Ca²⁺ waves → NCX1 (Na⁺/Ca²⁺ exchanger) forward mode activated (extrudes 1Ca²⁺, imports 3Na⁺ = net inward depolarizing current) → delayed afterdepolarization (DAD) → if DAD amplitude exceeds INa activation threshold → triggered action potential → salvos of triggered APs produce bidirectional VT. Bidirectional VT morphology reflects alternating bundle-branch exit blocks from Purkinje system triggered activity, not epicardial origin. (sources/channelopathies-jaha-2025, sources/membrane-potential-physrev-2021)
• Mechanism (CASQ2) — calcium release unit: Calsequestrin-2 functions within a quaternary calcium release unit (RYR2 + CASQ2 + triadin + junctin) anchored in the junctional SR. CASQ2 normally buffers luminal SR Ca²⁺ and inhibits RYR2 in the closed state by signalling through triadin and junctin. CASQ2 LOF (misfolding, impaired polymerization, or protein absence) disrupts this inhibitory signalling → RYR2 loses Ca²⁺-dependent gate control → spontaneous release even at lower SR Ca²⁺ loads → same NCX-DAD-triggered AP sequence as CPVT1, but without calsequestrin Ca²⁺ buffering, leading to earlier onset and greater severity. (sources/channelopathies-jaha-2025, sources/membrane-potential-physrev-2021)
• Mechanism (TECRL/TERL) — mixed CPVT/LQTS phenotype: TECRL encodes an oxidoreductase enzyme localized to the endoplasmic reticulum. Autosomal recessive. Homozygous TECRL pathogenic variants reduce RYR2 and CASQ2 protein levels, resulting in reduced SR calcium storage and aberrant calcium handling. The clinical phenotype is a distinctive overlap of both CPVT and LQTS features — not pure CPVT — making TECRL disease phenotypically distinct from CPVT1 (RYR2 GOF) and CPVT2 (CASQ2 LOF), with adrenergically triggered bidirectional VT coexisting with QT prolongation. (sources/genetics-va-fcvm-2022 — medium)
• ECG: Normal at rest. During exercise: polymorphic VT or bidirectional VT (180° QRS rotation beat-to-beat). CPVT PVCs are late-coupled; LBBB pattern with inferior axis is most sensitive/specific. (sources/channelopathies-jaha-2025)
• Diagnosis: Exercise stress test (Bruce protocol) is primary tool; provokes VT in ~2/3 of patients. "Burst" exercise protocol for higher sensitivity. Epinephrine infusion for those unable to exercise (VT induction with >10 PVCs/min or new T-wave alternans). 24-hr Holter for stress/emotional triggers. Genetic testing recommended for all clinically suspected cases + first-degree relatives. (sources/channelopathies-jaha-2025)
• Epinephrine challenge (2025 EHRA consensus): Appropriate only when exercise test is not feasible — exercise test has superior sensitivity. In 81 CPVT patients (31% RYR2 variant), epinephrine missed up to 70% of RYR2 patients who did not achieve sufficient heart rate vs. exercise (Marjamaa et al.). Positive criteria: >10 PVCs/min, 3 consecutive PVCs, recurrent couplets, bigeminal rhythm, or bidirectional VT; bidirectional VT is most specific for RYR2 P/LP variant. Epinephrine is NOT a substitute for exercise testing in CPVT. (sources/pharmacological-provocation-europace-2025 — high)
• Management: Exercise restriction. β-blockers (nonselective preferred) are cornerstone. ~30% require add-on therapy: flecainide (class IC) is first add-on. Alternatives: propafenone, verapamil, ivabradine, dantrolene (all limited evidence). LCSD for refractory pharmacological failure. ICD only as last resort — ICD shocks can provoke catecholamine surge, exacerbating arrhythmia; inappropriate shocks more common in CPVT than other channelopathies. Subcutaneous ICDs associated with higher complications. (sources/channelopathies-jaha-2025)

AHA/ACC 2025 Sports Statement — CPVT-Specific Guidance

• Gene+/phenotype- (no exercise-induced ectopy on burst exercise stress testing): Competitive sports participation reasonable; discuss prophylactic CPVT-directed medical therapy (BB ± flecainide). (sources/competitive-sports-aha-2025, rating: very high)
• Asymptomatic CPVT with exercise-induced ectopy: Competitive sports can consider after optimization of therapies (BB + flecainide) and normalization of stress test. Adequate suppression = ideally no ectopy; bigeminal PVCs may be acceptable; couplets or NSVT require continued intensification. (sources/competitive-sports-aha-2025)
• Previously symptomatic CPVT: Requires combination BB + flecainide, possibly LCSD, with normalized stress test before competitive sports. These individuals are higher-risk; closely monitor and reassess with burst exercise testing every 6–12 months. (sources/competitive-sports-aha-2025)
• Serial burst exercise stress testing 1–2 times/year is recommended for longitudinal monitoring of all CPVT athletes. (sources/competitive-sports-aha-2025)
• ICD should NOT be implanted solely for competitive sports participation — adrenergic storm triggered by shocks worsens CPVT arrhythmia; ~5%/year inappropriate shock risk. (sources/competitive-sports-aha-2025)
• This represents a meaningful shift from prior universal exercise restriction toward a stratified, SDM-guided approach based on genotype and stress test response. See concepts/Sports-Cardiology-SDM.
• Ca²⁺ Release Deficiency Syndrome (CRDS): A newly described RYR2 loss-of-function phenotypic spectrum distinct from classical CPVT. CRDS patients do not exhibit typical exercise-induced bidirectional VT; instead they present with short-coupled ventricular torsade-de-pointes arrhythmias. RYR2 exon 3 deletion has been associated with LVNC overlap and atypical CPVT. Loss-of-function RYR2 variants reduce Ca²⁺ release (vs. the gain-of-function excess release in CPVT1), producing a clinically distinct arrhythmia syndrome. (sources/arrhythmia-genetics-mgenetik-2025)
• Gene therapy: CASQ2 wild-type reconstitution; CRISPR/Cas9 silencing of mutant RYR2. (sources/channelopathies-jaha-2025)
• Gene editing candidacy: CPVT is identified as a strong candidate for gene editing in the risk-benefit framework for inherited cardiac conditions — pharmacological suppression (β-blockers + flecainide) is effective but not curative, and direct RYR2 or pathway correction targets the root genetic defect more definitively than devices or drugs. (sources/gene-editing-cv-tcm-2025 — medium; see concepts/Gene-Editing-Risk-Benefit-Framework)
• Direct RYR2 replacement is infeasible — gene is ~15,000 nt, far exceeding AAV packaging capacity (~4.7 kb). (sources/gene-therapy-arrhythmia-2025)
• AAV9-CASQ2 replacement abolished adrenergically induced VT in CASQ2 KO mice (Denegri 2012); single injection in CASQ2-R33Q knock-in mice achieved >85% arrhythmia reduction sustained ≥1 year (Denegri 2014). (sources/gene-therapy-arrhythmia-2025)
• CASQ2 overexpression also suppressed arrhythmias in RYR2-CPVT1 models — pathway-directed approach to bypass direct RYR2 targeting (Santiago Castillo 2023). (sources/gene-therapy-arrhythmia-2025)
• Allele-specific siRNA silencing of mutant CASQ2-R33Q: ~60% mRNA/protein reduction, prevented arrhythmias (Bongianino 2017). (sources/gene-therapy-arrhythmia-2025)
• CRISPR-SaCas9 targeting RYR2-R4496C: ~41% editing efficiency, 0/7 treated vs. 7/8 control had arrhythmias — first in-vivo CRISPR RYR2 repair (Pan 2023). (sources/gene-therapy-arrhythmia-2025)
• CaMKII inhibitory peptide (AIP) via AAV9: mutation-agnostic pathway modulation; suppressed Ca²⁺ dysregulation and arrhythmias in CASQ2 KO mice (Bezzerides 2019). (sources/gene-therapy-arrhythmia-2025)

Chang 2025 — Largest CPVT Clinical Database (Marks Lab)

• Systematic review of 221 publications (through Oct 2020): 964 CPVT patients with 263 unique RYR2 protein-coding variants — the largest CPVT compilation to date. (sources/RYR2-CPVT-CircEP-2025, rating: very high)

• Median age of CPVT onset: 11 years (IQR 7–14), range 0–66 years, right-skewed distribution. Lower in patients with polymorphic VT (10y vs 13.5y, P<0.001) and syncope (10y vs 14.5y, P<0.001).

• De novo vs inherited: 87 de novo, 186 inherited among those with inheritance reported. De novo patients had greater proportion of sudden cardiac arrest — genetic testing warranted even without family history.

• Stress-dependence confirmed: 315/321 (98.1%) with documented stress testing had polymorphic VT; 261/270 (96.7%) syncope events occurred during exercise/stress; 97/113 (85.8%) sudden cardiac arrests during exercise/stress.

• Variant distribution: 76.43% of variants reported in ≤3 patients — most are rare. Top 3: p.G357S (99 patients), p.R420Q (52), p.R420W (27). p.G357S frequency inflated by one large multi-generational family study.

• Structural determinants of severity: Variants in the core solenoid domain (CSol) and channel pore subdomain have earliest onset (median 8y vs 11y overall). EF-hand subdomain variants have latest onset (median 28y). Even variants at the same residue differ: p.R420Q median 10y vs p.R420W median 18.5y (P=0.012).

• Variant-specific β-blocker efficacy: p.G2337V 10/11 effective; p.R420W 5/17 (P=0.031 vs G2337V); p.C2277R 2/8 (P=0.047 vs G2337V). ~30% of patients require therapy beyond β-blockers.

• Variant-specific flecainide use (post-2013): p.S2246L 3/4, p.R420W 7/9, p.C2277R 6/8 vs p.G357S 0/91 and p.G2337V 0/21. p.R420W significantly more flecainide + BB than p.R420Q at the same residue (P=0.008).

• Variant-specific ICD use: p.S2246L 7/9, p.R420Q 13/24 vs p.G357S 1/94 and p.G2337V 1/21.

• Inter-family heterogeneity: p.M3978I — every case symptomatic; p.G155R — nearly all asymptomatic except one 16-year-old sudden death during sports.

• Web app: markslab-cpvtdb.org — publicly queryable database with 3D RYR2 structural visualization (Mol* Viewer).

• Hotspot refinement: Authors propose adding exons 37 and 42 to historical hotspot II based on additional unique variants found.

• Flecainide mechanism debate: Three competing lines of evidence: (1) Liu 2011 -- antiarrhythmic without affecting Ca2+ homeostasis (Na+ channel mechanism); (2) Kryshtal 2021 -- direct RYR2 inhibition demonstrated; (3) Bannister 2016 -- no direct RYR2 channel effect. Preclinical support for RYR2 open-state blockade: Hilliard 2010 showed flecainide inhibits RyR2 Ca2+ release channels by open-state blockade, reducing spark Ca2+ mass without causing compensatory SR Ca2+ loading -- preventing diastolic Ca2+ waves that drive triggered arrhythmias in CPVT mouse models. Clinical efficacy in CPVT is well-established; primary mechanism (Na+ channel vs direct RyR2 blockade) remains unresolved. (sources/flecainide-af-europace-2011, rating: medium; sources/RYR2-CPVT-CircEP-2025, rating: very high).

• Database serves as foundation for future ML-based pathogenicity predictor for RYR2 VUS.

• ESC 2022 guideline recommendations:

  • Non-selective beta-blockers (nadolol or propranolol): Class I in all patients with clinical CPVT diagnosis. (sources/VA-SCD-ESC-2022)
  • Avoid competitive sports, strenuous exercise, and stressful environments: Class I. (sources/VA-SCD-ESC-2022)
  • ICD + beta-blockers + flecainide after aborted CA: Class I (NEW 2022 upgrade — previously flecainide was Class IIa). (sources/VA-SCD-ESC-2022)
  • ICD when arrhythmic syncope or bidirectional/PVT despite max beta-blocker + flecainide: Class IIa (downgraded from Class I). (sources/VA-SCD-ESC-2022)
  • LCSD when flecainide + beta-blockers are ineffective, not tolerated, or contraindicated: Class IIa (upgraded from IIb). (sources/VA-SCD-ESC-2022)
  • Epinephrine/isoproterenol challenge when exercise test not possible: Class IIb. (sources/VA-SCD-ESC-2022)
  • PES for SCD risk stratification: NOT recommended (Class III). (sources/VA-SCD-ESC-2022)

Contradictions / Open Questions

• Reshuffled CPVT ICD hierarchy between 2015 and 2022 ESC guidelines: In 2015, ICD was Class I for patients with arrhythmic syncope and/or documented bidirectional/PVT on maximum beta-blocker + flecainide — the highest evidence class. In 2022, this was downgraded to Class IIa, while ICD + flecainide + beta-blockers after aborted CA was simultaneously upgraded to Class I. This reflects a shifting view that ICD in CPVT is most clearly indicated post-SCA, but creates ambiguity for the large group of symptomatic patients who have not yet arrested. (sources/VA-SCD-ESC-2022)
• ICD-triggered adrenergic cascade in CPVT: ICD shocks cause catecholamine surges that can exacerbate CPVT arrhythmias — potentially worsening the very condition they treat. This ICD-proarrhythmia risk is unique to CPVT and makes ICD implantation a last resort, yet its formal Class I status after aborted CA leaves clinicians with conflicting imperatives. (sources/channelopathies-jaha-2025, sources/VA-SCD-ESC-2022)
• LCSD upgrade from IIb to IIa: The upgrade of LCSD for refractory CPVT is based on expanding observational data but still lacks RCT support — the threshold for recommending a surgical procedure remains unvalidated prospectively. (sources/VA-SCD-ESC-2022)
• Variant-specific treatment — biological signal vs sample size: Chang 2025 demonstrated statistically significant differences in β-blocker efficacy, flecainide use, and ICD implantation between specific RYR2 variants. However, per-variant sample sizes range from 3 to 91 patients, and the data are retrospectively extracted from heterogeneous publications. The biological signal is strong (different residues at the same amino acid → different outcomes), but individual variant sample sizes are insufficient to drive guideline-level recommendations. This creates tension: the data argue for personalized variant-specific management while lacking the statistical power to define variant-specific protocols. (sources/RYR2-CPVT-CircEP-2025)
• Flecainide mechanism in CPVT — unresolved debate: Three competing findings exist: (1) flecainide prevents arrhythmias without affecting Ca²⁺ homeostasis → Na⁺ channel mechanism (Liu 2011); (2) flecainide directly inhibits RYR2 (Kryshtal 2021); (3) flecainide has no direct effect on RYR2 channel activity (Bannister 2016). The clinical efficacy of flecainide in CPVT is well-established, but whether it acts via Na⁺ channel blockade, direct RYR2 inhibition, or both remains unresolved. (sources/RYR2-CPVT-CircEP-2025)
• RYR2 variant penetrance heterogeneity: Chang 2025 documented extreme inter-variant penetrance variation: p.M3978I — every carrier symptomatic; p.G155R — nearly all carriers asymptomatic except one 16-year-old sports-related sudden death. This degree of penetrance variability within the same gene complicates cascade screening counseling and VUS interpretation. The molecular basis for these penetrance differences is unknown. (sources/RYR2-CPVT-CircEP-2025)
• ClinGen disputes PKP2 and KCNJ2 in CPVT (01/2021): Two genes frequently attributed to CPVT — PKP2 (the primary ARVC desmosomal gene) and KCNJ2 (the Andersen-Tawil syndrome gene) — are classified as "Disputing" for CPVT by ClinGen (01/20/2021). CASQ2 has an interesting dual classification: definitive for AR CPVT2, but only moderate for AD CASQ2-CPVT. TRDN (triadin) and TECRL are both definitively established as AR CPVT genes, important additions to diagnostic panels. CALM1, CALM2, and CALM3 are moderate — meaningful enough for panel inclusion but not yet definitive. (sources/clingen-summary-2026-05-09, rating: high)

Connections

• Related to concepts/Electrical-Remodeling
• Related to sources/membrane-potential-physrev-2021
• Related to concepts/Pharmacological-Provocation-Testing
• Related to concepts/Bidirectional-Ventricular-Tachycardia
• Related to concepts/Left-Cardiac-Sympathetic-Denervation
• Related to concepts/CRISPR-Cas9-in-Channelopathies
• Related to concepts/iPSC-Derived-Cardiomyocytes
• Related to concepts/Sudden-Cardiac-Death
• Related to concepts/AAV-Gene-Delivery
• Related to concepts/Gene-Silencing-Therapy
• Related to entities/RYR2
• Related to entities/Andersen-Tawil-Syndrome
• Related to concepts/Electrical-Storm
• Related to concepts/Cardiogenetic-Centers
• Related to concepts/Sports-Cardiology-SDM
• Related to sources/competitive-sports-aha-2025
• Related to sources/RYR2-CPVT-CircEP-2025
• Related to entities/Flecainide
• Related to concepts/ClinGen-Gene-Disease-Validity
• Related to sources/clingen-summary-2026-05-09

Sources

• sources/flecainide-af-europace-2011
• sources/genetics-va-fcvm-2022